Cantor Fitzgerald initiated coverage of BridgeBio Oncology (BBOT) with an Overweight rating.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks